Ajanta Pharma Share Price

    NSE
    2574.1
    +53.40 (2.12%)
    AJANTPHARM • 30 Jun, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    13.83%

    3Y Annualised Return

    26.87%

    5Y Annualised Return

    21.97%

    The current prices are delayed, login or Open Demat Account for live prices.

    Ajanta Pharma Stock Performance

    1W Return0.36
    1Y Return12.54
    Today's Low2543.2
    Prev. Close2,520.70
    Mkt Cap (Cr.)32,153.62
    1M Return2.52
    3Y Return108.33
    52-Week High3485
    Open2,550.00
    PE Ratio35.48
    6M Return-12.88
    Today's High2584.1
    52-Week Low2160.15
    Face Value2

    Ajanta Pharma Company background

    Founded in: 1979
    Managing director: Yogesh Agrawal
    Ajanta Pharma Limited is a specialty pharmaceutical formulation company primarily with a welldiversified Branded Generics business spread across India, the Rest of Asia, and Africa. The Company is involved in development, manufacturing and marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments. It has strong chronicfocused product portfolio led by a firsttomarket strategy and frontend presence which helps it outgrow the market. The companys business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia. In India, the Company has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management.In branded generic business in emerging markets in Asia and Africa, Ajanta Pharmas products cater to therapeutic segments like AntiBiotic, AntiMalarial, AntiDiabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory General Health products. The companys institutional business comprises of supplies to various government bodies in India and supply of AntiMalarial products under WHO approved programs in Africa.Ajanta Pharma operates 7 stateoftheart manufacturing facilities in India and Mauritius. 2 of the facilities in India have been approved by USFDA. The company has an advanced Research Development Centre in Mumbai for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms. Its RD centre has a team of over 750 scientists working on innovative products for various markets across the globe. Established in 1973 and headquartered in MumbaiIndia, the company has a mission of Serving Global Health Care Needs Worldwide. Ajanta has been consistently providing affordable and quality medicines to patients in different parts of the world. The company began its operation in the year 1973 by setting up a small repackaging unit. The company also launched 4 products under its own brand name for repackaged pharma items in the same year. In 1979, the Company set up its 1stManufacturing factory in Chikalthana, Maharashtra and also launched 1st own manufactured OTC product Pinkoo Gripe Water, making a mark in the industry by deviating from easy path of following leaders in gripe water industry. A New Manufacturing Facility was built by the company in the year 1984 in Paithan and the company also entered in institutional business. During the period from 1995 to 1998, the company established dedicated RD facility at Kandivli and also set up manufacturing facilities in Mauritius and CIS. In 2000, the company went public with shares by listing shares in BSE and NSE and also undertook major expansion of manufacturing facilities. In 2002, the company entered domestic prescription market with speciality segment force. In 2007, the company expanded its RD facility with independent premises in Kandivali. The company also got USFDA Approval for its Paithan manufacturing facility in 2008. In 2009, the company started Active Pharmaceutical Ingredient (API) plant in Waluj, Aurangabad for captive use. During the year, the company bought a manufacturing facility at Chitegaon in Aurangabad, Maharashtra to fuel the companys growth. Also during the year, Ajanta Pharma became the first generic company in the world to get WHO Geneva Prequalification for AntiMalarial Drug.In 2010, Ajanta Pharma entered Philippines market with unique product portfolio through Ajanta Pharma Philippines Inc. In 2011, Ajanta Pharma emerged as a strong speciality player in domestic market in Ophthalmology, Dermatology and Cardiology with many brands holding leadership positions.In 2012, Ajanta Pharma was ranked among the Top 10 pharma companies in Franco Africa. During the year 2013, Ajanta Pharma commenced sales to the US market. In 2014, the company set up its 2nd dedicated RD centre at Kandivli in Mumbai for India and emerging markets. During the year, the company inaugurated a new facility in Dahej, Bharuch, Gujarat for catering to the requirements of markets like USA, WHO and emerging markets. In 2015, the company announced the launch of Montelukast Sodium Oral Granules. The company also announced the launch of Montelukast IR Tablets and Montelukast Chewable Tablets in US market.In 2017, the company inaugurated and commissioned 1st phase at a new facility in Guwahati, Assam. The companys Dahej, Gujarat facility was approved by the USFDA without any observation in April 2017.On 11 July 2017, Mr. Yogesh M. Agrawal, Managing Director of Ajanta Pharma (APL) informed the company that promoters have sold 27 lakh equity shares in APL, representing about 3.07% of APLs equity shares. Consequent to sale, promoter holding has come down from 73.78% to 70.71% in APL. This sale has been done to provide liquidity to the promoters and the proceeds will be utilized for personal use.On 9 February 2018, Ajanta Pharma announced that its formulation facility at Dahej in Gujarat was inspected by USFDA from 5 to 9 February 2018. At the end of the inspection, no Form 483 was issued to the company by the USFDA.As on 31 March 2018,the company has six subsidiaries overseas, including one step down subsidiary under its roof.The companys capex investment in manufacturing facilities and RD which has taken the total from Rs 997 crore in FY 2017 to Rs 1,225 crore in FY 2018.The Company had convened ExtraOrdinary General Meeting on 10th October 2017 as per the directions of National Company Law Tribunal for obtaining consent of shareholders for merger of Gabs Investments Private Ltd. with the Company.During the FY2019, companys wholly owned subsidiary viz., Ajanta Pharma UK Limited was dissolved on 18th December 2018. Post that, the company has five operating subsidiaries overseas, including one step down subsidiary.The total capex for FY 2019 was Rs 361 crore and propose to spend further Rs 350 crore in FY 2020, mainly on Guwahati, Pithampur and corporate office in Mumbai.in March 2019, the Company bought back 7,69,230 (Seven lakhs sixtynine thousand two hundred and thirty only) fully paidup equity shares of the face value of Rs 2/ each at a price of Rs 1300 per share for an aggregate amount of Rs 100 crore.The Scheme of Amalgamation and Arrangement of Gabs Investments Pvt. Ltd. with the Company which was filed by the Company with National Company Law Tribunal (NCLT) in the last year, was rejected by NCLT on grounds cited in its order. The Company had preferred an appeal before the National Company Law Appellate Tribunal (NCLAT) challenging the order of NCLT. However, after considering all the pros and cons at length, it was deemed appropriate to withdraw the appeal. Accordingly, the same was withdrawn on 7th December 2018.During the FY2020, third phase of Guwahati plant, new manufacturing facility in Pithampur, Madhya Pradesh and new R D building in Kandivli, Mumbai were completed and became fully functional. Expansion of facility at Dahej has been commenced and the same is expected to be over by December 2020. During the year, an amount of Rs 245 crore was incurred on capex.The Board of Directors have approved buyback proposal on 3 November 2020, for purchase by the Company of up to 7,35,000 shares of Rs 2 each (representing 0.84% of total paidup equity capital) from the shareholders of the Company on a proportionate basis by way of a tender offer at a price of Rs 1,850 per equity share for an aggregate amount not exceeding Rs 135.98 crore in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulations, 2018.During the quarter ended 31 December 2020,the group had bought back its 735000 equity shares of Rs 2/each at Rs 1850 per share for an aggregate amount of Rs 135.98 crore and extinguished those shares on 30 December 2020.The Company launched 16 new products in FY 2022, including four 1st to market products in the country. During the year 2022, it launched 3 new products and filed 8 ANDAs. It received 2 final and 1 tentative approval. There are 20 ANDAs awaiting approval from US FDA.The Company launched 23 new products in FY 2023 with six firsttomarket products.In 2024, Company launched 27 new products. It has expanded the product portfolio with the launching of 25 new products in chronic therapies in 2025.

    As of 30 Jun, 2025, Ajanta Pharma share price is ₹2574.1. The stock opened at ₹2550 and had closed at ₹2520.7 the previous day. During today’s trading session, Ajanta Pharma share price moved between ₹2,543.20 and ₹2,584.10, with an average price for the day of ₹2563.65. Over the last 52 weeks, the stock has recorded a low of ₹2,160.15 and a high of ₹3,485.00. In terms of performance, Ajanta Pharma share price has declined by 15.4% over the past six months and has increased by 13.83% over the last year.

    Read More
    Ajanta Pharma SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹69,72,655 (+7.27%)

    Daily SIP of 25,000 would have become 69,72,655 in 1 year with a gain of 4,72,655 (+7.27%)

    View details of Market Depth

    Ajanta Pharma Fundamental

    Market Cap (in crs)

    32,153.62

    Face Value

    2

    Turnover (in lacs)

    3,384.30

    Key Metrics

    Qtr Change %
    26.14% Fall from 52W High
    -1.9
    Dividend yield 1yr %
    Below industry Median
    1.1

    Ajanta Pharma Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Ajanta Pharma Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    1170.41 Cr
    1146.13 Cr
    1186.64 Cr
    1144.92 Cr
    1054.08 Cr
    Ajanta Pharma Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    4742.6 Cr
    4293.31 Cr
    3841.28 Cr
    3456.67 Cr
    2915.67 Cr
    2680.06 Cr
    Ajanta Pharma Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    225.26 Cr
    232.88 Cr
    216.48 Cr
    245.77 Cr
    202.72 Cr
    Ajanta Pharma Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    920.39 Cr
    816.17 Cr
    587.98 Cr
    712.68 Cr
    653.87 Cr
    467.7 Cr

    Ajanta Pharma Result Highlights

    • Ajanta Pharma Ltd reported a 7.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 18.6%.

    • Its expenses for the quarter were down by 6.6% QoQ and up 5.9% YoY.

    • The net profit decreased 13.0% QoQ and increased 65.8% YoY.

    • The earnings per share (EPS) of Ajanta Pharma Ltd stood at 16.1 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Ajanta Pharma

    Promoter
    66.3%
    Foreign Institutions
    8.9%
    Mutual Funds
    15.1%
    Domestic Institutions
    17.5%
    Public
    7.4%
    Promoter
    66.3%
    Foreign Institutions
    9.3%
    Mutual Funds
    14.9%
    Domestic Institutions
    17%
    Public
    7.4%
    Promoter
    66.3%
    Foreign Institutions
    9.1%
    Mutual Funds
    14.9%
    Domestic Institutions
    17.1%
    Public
    7.5%
    Promoter
    66.3%
    Foreign Institutions
    8.4%
    Mutual Funds
    14.8%
    Domestic Institutions
    17.4%
    Public
    7.9%
    Promoter
    66.2%
    Foreign Institutions
    8.5%
    Mutual Funds
    14.8%
    Domestic Institutions
    17.5%
    Public
    7.8%
    Promoter
    66.2%
    Foreign Institutions
    9.1%
    Mutual Funds
    13.9%
    Domestic Institutions
    16.7%
    Public
    8%

    Ajanta Pharma Technical Analysis

    Moving Averages Analysis
    2574.1
    Current Price
    Bullish Moving Averages
    5
    Bearish Moving Averages
    11
    5Day EMA
    2,562.10
    10Day EMA
    2,569.60
    12Day EMA
    2,571.90
    20Day EMA
    2,578.10
    26Day EMA
    2,581.20
    50Day EMA
    2,593.90
    100Day EMA
    2,634.40
    200Day EMA
    2,650.80
    5Day SMA
    2,562.50
    10Day SMA
    2,564.00
    20Day SMA
    2,585.80
    30Day SMA
    2,583.80
    50Day SMA
    2,599.90
    100Day SMA
    2,606.30
    150Day SMA
    2,696.00
    200Day SMA
    2,806.20
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    83741 Rs
    133392 Rs
    Week Rs
    111015 Rs
    162825 Rs
    Month Rs
    88142 Rs
    145388 Rs
    2,567.13
    Pivot
    Resistance
    First Resistance
    2,591.07
    Second Resistance
    2,608.03
    Third Resistance
    2,631.97
    Support
    First Support
    2,550.17
    Second support
    2,526.23
    Third Support
    2,509.27
    Relative Strength Index
    49.18
    Money Flow Index
    50.40
    MACD
    -9.27
    MACD Signal
    -5.47
    Average True Range
    68.45
    Average Directional Index
    19.33
    Rate of Change (21)
    2.52
    Rate of Change (125)
    -15.44
    Name
    Holding Percent
    Uti-Flexi Cap Fund
    2.96
    Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund
    2.84
    Kotak Small Cap Fund
    1.46
    Canara Robeco Mutual Fund A/C Canara Robeco Emerging Equities
    1.38
    Hdfc Large And Mid Cap Fund
    1.25
    Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 110
    1.25

    Ajanta Pharma Latest News

    30 JUN 2025 | Monday

    Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    26 JUN 2025 | Thursday

    Ajanta Pharma Ltd - 532331 - Closure of Trading Window

    19 JUN 2025 | Thursday

    Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication

    View More

    Ajanta Pharma Share Price FAQs

    Ajanta Pharma share price is ₹2574.1 in NSE and ₹2566.25 in BSE as on 30/6/2025.

    Ajanta Pharma share price in the past 1-year return was 12.54. The Ajanta Pharma share hit a 1-year low of Rs. 2160.15 and a 1-year high of Rs. 3485.

    The market cap of Ajanta Pharma is Rs. 32153.62 Cr. as of 30/6/2025.

    The PE ratios of Ajanta Pharma is 35.47 as of 30/6/2025.

    The PB ratios of Ajanta Pharma is 8.86 as of 30/6/2025

    The Mutual Fund Shareholding in Ajanta Pharma was 15.13% at the end of 30/6/2025.

    You can easily buy Ajanta Pharma shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Ajanta Pharma share price is ₹3485 and ₹2160.15 as of 30/6/2025.

    Please be aware that Ajanta Pharma stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    820.35
    +14.95 (+1.86%)
    1,500.60
    -14.80 (-0.98%)
    2,001.50
    -13.40 (-0.67%)
    1,601.80
    -6.20 (-0.39%)
    3,462.00
    +20.90 (+0.61%)
    Top Gainers
    6,217.50
    +198.00 (+3.29%)
    820.35
    +14.95 (+1.86%)
    421.50
    +7.00 (+1.69%)
    872.10
    +14.40 (+1.68%)
    326.75
    +3.30 (+1.02%)
    Top Losers
    1,098.90
    -25.40 (-2.26%)
    1,199.20
    -25.90 (-2.11%)
    2,163.50
    -44.40 (-2.01%)
    4,237.10
    -83.20 (-1.93%)
    12,400.00
    -242.00 (-1.91%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -